New imaging test aims to predict chemotherapy outcomes in rare brain cancer
NCT ID NCT05222269
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tested whether a special PET scan using a tracer called 68Ga-PentixaFor could predict how well patients with central nervous system lymphoma respond to chemotherapy. The plan was to scan patients before, during, and after treatment and see if the scan results matched their long-term outcomes. However, the trial was stopped early after enrolling only one person, so we do not have enough information to know if this approach works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- 68Ga-PentixaFor (a radioactive tracer for PET imaging)
- What this could lead to
- If successful, this imaging method could help doctors predict which patients will respond to chemotherapy, potentially guiding more personalized treatment.
- What could go wrong
- The trial was terminated after enrolling only 1 participant, so no meaningful conclusions can be drawn. It is unclear if the approach works or is practical.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CNS LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University Hospital Aalborg
Aalborg, 9000, Denmark
-
University Hospital CHU Nantes
Nantes, 44093, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.